Replies to post #470181 on Anavex Life Sciences Corp (AVXL)

[kund]

As per Misleading’s calendar year 2030 is also near term.

[nidan7500]

Near term catalysts that will create an upward jump in AVXL stock value

georgejji

"Well Done ", georgejji

It is also notable that the EMA has established by provision of objective evidence that amyloid is not a cause for AD AND they have just noted that AVXL is (has) one of 4 last remaining new drugs on their lists of trial finalists....AKA..."What color is this RED piece of Paper?"...

[Hoskuld]

I think we can forget about any new trials starting this year. Maybe PD trial in Australia. Maybe.

IMO, MAA submission would be nice and could provide a brief bump but expect that to be short-lived. The most impactful event over the next year could be the 3-71 result - but with only ~20 patients in Part B of the study, it is possible that the signal will be minimal and blunt that impact.

[XenaLives]

We are dealing with a new, medically induced epidemic. I suspect that statistically this epidemic exceeds naatural "Alzheimers" and other neurotoxins by orders of magnitude. I also believe that there are political entities that would keep blarcamesine off the market because it would provide relief.

Look aat your own extened family and test this premise.

[Search Labs | AI Overview
Learn more
…
Both gadolinium and fluoroquinolones can cause mitochondrial damage, which can lead to cell death and other serious health issues:
Gadolinium
Gadolinium-based contrast agents (GBCAs) can damage mitochondria by blocking calcium channels and increasing mitochondrial membrane fluidity. This can lead to a decrease in ATP synthesis, depolarization of the mitochondrial membrane, and cytochrome c release. In one study, gadolinium chloride exposure to rat cortical neurons caused a significant decrease in mitochondrial metabolic activity within three hours.
Fluoroquinolones
Fluoroquinolones can damage mitochondria by inhibiting DNA Gyrase, which is required for healthy cell production. This can lead to cell death and other serious health issues, including damage to the nervous system, muscles, joints, and tendons. In some cases, fluoroquinolone toxicity can be fatal.
Gadolinium can be retained in the body for months or years, including in the brain, bones, and skin. Symptoms of Gadolinium Deposition Disease (GDD) include brain fog, fatigue, headache, muscle twitching, and insomnia. quote]

[ExtremelyBullishZig]

That's some volume today, George. Thank you for the further vote of confidence with this list of catalysts. You sure are shaping up to be the financial advisor that many are here for.

[Bourbon_on_my_cornflakes]

Rubbish: Near term catalysts that will create an upward jump in AVXL stock value

The only one that would matter is the second one: Full regulatory submission of
blarcamesine in Europe (EMA)

Chances of it happening in 2024-2025 only 50-50.